Healthcare press releases — Press Release Database

Finance · Healthcare

Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell’s Phase 3 Metastatic Breast Cancer Study

PHILADELPHIA and VANCOUVER, British Columbia, Sept. 14, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces that the independent Data Safety Monitoring Board (DSMB) has issued its seventh consecutive positive recommendation following review of clinical data from BriaCell’s pivotal Phase 3 Bria-ABC study of Bria-IMT plus immune checkpoint inhibitor (CPI) in patients with metastatic breast cancer ( NCT06072612 ).

Sep 14 · 11:30GlobeNewswire

Finance · Healthcare

Lost Money on Fractyl Health, Inc. (GUTS)? Urged to Join Class Action ...

(PR-inside.com) NEW YORK, NY / ACCESS Newswire / September 14, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Fractyl Health, Inc. (NASDAQ:GUTS) securities. If you suffered a loss on your Fractyl Health, Inc. investment and would like to explore a potential recovery under the federal securities laws, Learn about Fractyl Health, Inc. Class Action or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder advocates. THE LAWSUIT: A class action securities lawsuit was filed against ..

Sep 14 · 11:25PR-Inside

Healthcare

Altrova Health Inc. to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto

Toronto, Ontario--(Newsfile Corp. - September 14, 2026) - Altrova Health Inc. (CSE: ROVA) (OTCQB: ATVHF) (FSE: WF8) ("Altrova Health" or the "Company") is pleased to announce its participation in the upcoming 3rd Annual ArcStone-Kingswood Growth Summit in Toronto, taking place on September 16, 2026, at the Sheraton Center Toronto Hotel. Geoff Benic, Chief Executive Officer of Altrova Health, will be presenting on the company's recent milestones and future growth strategy.The ArcStone-Kingswood...

Sep 14 · 11:09mlpr-newsfile

AI · SaaS

Regenerative Medical Technology Group, Inc. Details Expanded ISSCA AI(TM) Clinical Intelligence Platform, Including Protocol-Native Engine, Structured Data Assets, and Multi-Line Commercial Model

Physician-controlled lab-to-plan workflow, ISSCA protocol ingestion, licensed technology partnership, and clinic-facing SaaS and membership design - with the physician remaining the decision-maker

Sep 14 · 11:01Newswire.com

Healthcare

Lysoway Therapeutics Announces Preclinical Data Supporting First-in-Class TRPML1 Agonist LW-1017 in Scientific Reports

CAMBRIDGE, Mass., September 14, 2026--Lysoway Therapeutics, a clinical-stage biotechnology company pioneering therapeutics targeting lysosomal ion channels for age-related neurodegenerative diseases, today announced the publication of preclinical data evaluating its lead candidate, LW-1017, in Scientific Reports, a journal from Nature Portfolio.

Sep 14 · 11:00mlpr-businesswire

Healthcare · Retail

Promino Holds Rejuvenate Muscle Health(TM) U.S. Retail Pricing as Whey Protein Costs Remain at Record Levels

WPC80 whey pricing has increased more than fivefold since 2023, reaching approximately US$14.50/lb in 2026Rejuvenate remains US$24.99 for 14 servings and US$39.99 for 30 servings at U.S. retail — as much as 40% lower per serving than a current leading 2-lb whey benchmarkPublished human research supports the ability of a low-dose leucine-rich essential amino acid formulation to stimulate muscle protein synthesis comparably to 20g of whey proteinRejuvenate is available in approximately 6,800 CVS...

Sep 14 · 11:00mlpr-newsfile

Healthcare

Q32 Bio Appoints José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer

-- Dr. Trevejo is a physician-scientist and biotechnology executive with over 20 years of experience spanning dermatology and late-stage clinical development -- -- Dr. Hershberger is a drug development leader with over 30 years of experience spanning late-stage development operations and...

Sep 14 · 10:59PR Newswire

Healthcare

BD Advances Intelligent Robotics to Transform the Future of Pharmacy Care at Fairview

First-of-its-kind U.S. deployment of BD Vmax 160 expands pharmacy automation beyond traditional dispensing, helping health systems manage growing demand for specialty therapies, refrigerated medications, and increasingly complex fulfilment needs FRANKLIN LAKES, N.J., Sept. 14, 2026...

Sep 14 · 10:50PR Newswire

Finance · Healthcare

Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

CARLSBAD, Calif., Sept. 14, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced the...

Sep 14 · 10:45PR Newswire

Finance · Healthcare

FDA Approves Telix’s Brain Cancer Imaging Drug Pixclara

MELBOURNE, Australia and INDIANAPOLIS, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Pixclara® (floretyrosine F 18 or 18 F-FET), an amino acid positron emission tomography (PET) drug for imaging gliomas (brain cancer).

Sep 14 · 10:30GlobeNewswire

Healthcare

Multi4 Medical Publishes Landmark Clinical Study in Prestigious BJUI - Initiates First Patient Treatments in Europe

First-in-human study in British Journal of Urology International confirms bladder cancer treatment can shift from the operating room to the outpatient clinic-enabling complete treatment and diagnostic sampling in minutes on awake patients. GOTHENBURG, Sweden, Sept. 14, 2026 /PRNewswire/...

Sep 14 · 10:30PR Newswire

Finance · Healthcare

Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors

SEATTLE, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced a clinical trial collaboration agreement with Merck (NYSE: MRK), known as MSD outside of the United States and Canada.

Sep 14 · 10:16GlobeNewswire